More news
> All Top Headlines
Expert Opinion
See all »
Written by Dr. Chepsy Philip from Believers Church Medical College Hospital, Tiruvalla, Kerala, India KEYNOTE-087 is a multicentre, single-arm, multicohort, nonrandomized, phase
More
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam Roy &
More
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic
More
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with the COMMANDS
MoreVideo News
See all »
By Dr. Lei Deng University of Washington & Fred Hutch Watch Dr. Lei Deng’s overview of the KEYNOTE-671
More
Dr. Talha Badar of Mayo Clinic discusses the results of Quantum First, a randomized, phase III trial evaluating the efficacy of Quizartinib
More
Dr. Richa Parikh interviewed Dr. Shaji Kumar of Mayo Clinic about his recommendations for the treatment of myeloma.
More
Dr. Dipesh Uprety interviewed Dr. Chadi Nabhan about his new book, Toxic Exposure. Watch the video to hear more about the book
MoreNew Approvals
See all »
On October 11, 2023, the U.S. Food and Drug Administration granted approval to Encorafenib (BRAF inhibitor) with Binimetinib (MEK inhibitor) for patients
More
On September 26, the U.S. Food and Drug Administration expanded the approval of bosutinib (Bosulif) to include pediatric patients 1 year of
More
By Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration approved HEPZATO KIT – which
More
By Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval to Elranatamab-bcmm
More
